Today, Hangzhou Kangji Weijing Medical Robotics Co., Ltd. (hereinafter referred to as “Weijing Medical”) made an announcement that it has successfully secured a Series B+ financing round amounting to hundreds of millions of yuan.

In this financing round, Guotai Junan Innovation Investment Co., Ltd. was the sole investor. Additionally, Kangji Medical, a strategic shareholder of Weijing Medical, also made supplementary investments. Gelu Capital played the role of the exclusive financial advisor for this financing endeavor.

The funds raised from this round will be strategically allocated. A significant portion will be utilized to expedite the commercialization process of the company's products. Moreover, it will drive forward the development and clinical registration of next-generation products, enabling Weijing Medical to stay at the forefront of medical innovation.

Weijing Medical boasts a highly talented core team, many of whom hail from the prestigious Harbin Institute of Technology. The company's flagship product, a four-arm laparoscopic surgical robot, achieved a major milestone by obtaining its registration certificate in April 2025. Since then, it has been undergoing rigorous trials in more than 10 top-tier hospitals across the country, demonstrating its potential to revolutionize the field of laparoscopic surgery.